POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Poly Medicure Ltd published audited standalone and consolidated financial results for Q4 and FY 2025-26 in Financial Express and Jansatta on May 26, 2026. Consolidated total income grew 13.4% YoY to ₹1,99,534 lakh, driven by strong quarterly revenue of ₹55,227 lakh in Q4. However, consolidated net profit after tax declined to ₹32,073 lakh from ₹33,856 lakh the prior year, with Q4 net profit falling nearly 30% to ₹6,504 lakh. Earnings per share (consolidated, basic) dropped to ₹31.79 from ₹34.13 annually. Standalone performance was stronger, with net profit rising to ₹33,598 lakh from ₹33,133 lakh. An exceptional charge of ₹680.40 lakh was recorded due to the implementation of new Labour Codes, impacting standalone results. Statutory auditors issued an unmodified (clean) opinion.
Revenue growth is healthy but the decline in consolidated net profit and EPS despite higher sales signals margin pressure, which could concern investors. The clean audit opinion and strong standalone performance provide some comfort. Watch for cost drivers in the full detailed filing.